The Legal Standard: What Pharmaceutical Companies Must Warn About
Pharmaceutical manufacturers have a continuing legal duty to monitor the safety of their products after FDA approval and to update their labeling when new safety information comes to light. This duty of post-market surveillance and label updating is codified in FDA regulations at 21 C.F.R. § 314.81(b)(2)(i), which requires manufacturers to report and disclose newly identified risks. Under product liability failure-to-warn doctrine, a manufacturer can be held liable for injuries caused by an undisclosed risk if it knew or reasonably should have known about that risk through the exercise of due diligence — including review of adverse event reports, published medical literature, and pharmacovigilance data.
The learned intermediary doctrine — a defense often invoked by pharmaceutical companies — holds that a drug manufacturer satisfies its duty to warn by providing adequate warnings to prescribing physicians, who then relay that information to patients. However, this doctrine has significant limitations in the Suboxone context: prescribers were themselves not warned about the dental risk, and therefore could not counsel patients to take protective measures such as rinsing after each dose, waiting before brushing, or scheduling more frequent dental evaluations.
The Timeline of Known Risk vs. Disclosed Risk
Suboxone sublingual film received FDA approval in 2010. Published case reports linking sublingual buprenorphine formulations to dental decay began appearing in peer-reviewed dental and addiction medicine journals in 2012 and 2013. Adverse event reports to the FDA's Adverse Event Reporting System (FAERS) describing dental injuries in buprenorphine sublingual users accumulated over the following years. By 2015 to 2016, the association was being discussed in dental professional forums and clinical publications. Through all of this period, Indivior's prescribing information and patient medication guides contained no meaningful dental safety warnings.
It was not until the FDA mandated new labeling on January 12, 2022 — more than a decade after Suboxone film's approval — that dental warnings were added to the product's labeling. Plaintiffs' attorneys argue that this twelve-year gap between the drug's approval and the addition of dental warnings, during which adverse event reports accumulated and medical literature documented the risk, constitutes a failure to fulfill the manufacturer's duty to warn that caused thousands of patients to sustain preventable dental injuries.
Indivior's Corporate History and Context
Indivior was spun off from Reckitt Benckiser in December 2014, inheriting the Suboxone product line and all associated regulatory and legal obligations. This is not the company's first encounter with product liability litigation: in 2019, Indivior pled guilty to a federal felony charge of making false statements to Medicaid about the relative safety of Suboxone film compared to generic alternatives, agreeing to pay $600 million in fines. This prior conduct is relevant background in Suboxone dental injury litigation, as it speaks to Indivior's approach to safety disclosures and its prioritization of market position over patient safety. Discovery in MDL 3092 is expected to probe Indivior's internal knowledge of the dental risk and the company's decision-making process regarding label updates.
Frequently Asked Questions
Related Pages
Suboxone Dental Damage Explained
Suboxone sublingual film strips damage teeth through a chemical acid erosion mechanism. Citric acid in the film creates a highly acidic oral environment during dissolution, dissolving tooth enamel with repeated daily exposure. This process is distinct from ordinary tooth decay and produces a characteristic pattern of rapid, widespread, smooth-surface erosion that dentists can document in dental records.
Suboxone Statute of Limitations by State
Suboxone dental injury claims are subject to state product liability statutes of limitations, typically 2 to 3 years, which may run from the January 12, 2022 FDA safety communication under the discovery rule. Deadlines vary significantly by state and individual circumstances — time is critical and consultation with an attorney is the only reliable way to determine your specific deadline.
Suboxone Dental Records and Evidence Gathering
Dental records — including clinical notes, X-rays, and billing documentation — are the evidentiary foundation of every Suboxone dental injury claim. Gathering them promptly is critical because dental practices have limited record retention requirements and older records may be unavailable from closed or sold practices.
Suboxone Settlement Amounts and Expectations
Reported Suboxone dental injury settlements have ranged from approximately $35,000 for minor-to-moderate cases to $250,000 or more for complete tooth loss requiring full-mouth reconstruction. The MDL is ongoing and no global settlement has been announced — individual case values depend heavily on injury severity, documentation quality, and state-specific legal factors.
The FDA Suboxone Dental Warning — January 2022
On January 12, 2022, the FDA issued a formal drug safety communication confirming that buprenorphine medicines dissolved in the mouth — including Suboxone film — can cause severe dental problems. The FDA reviewed 305 adverse event reports and found widespread, serious dental injuries requiring extractions, root canals, and full reconstruction. This communication is legally significant as the potential trigger date for the statute of limitations under the discovery rule for thousands of patients.
Suboxone Dental Injury Qualification Criteria
Not every Suboxone user who experienced dental problems has a viable legal claim. Qualifying cases generally involve significant dental injuries — multiple cavities, extractions, tooth loss, or reconstruction — developed during Suboxone use, documented in dental records, and timely filed. Understanding the criteria helps patients determine whether to pursue a claim.
Suboxone vs. Generic Buprenorphine Film
The dental injury risk from buprenorphine sublingual film is not unique to the Suboxone brand — generic buprenorphine/naloxone sublingual films share the same acidic excipient mechanism and the same dental injury profile. However, pursuing claims against generic manufacturers involves different legal considerations than brand-name product liability claims under both federal and state law.
Suboxone Dental Treatment Costs
Dental rehabilitation costs for Suboxone-related injuries can range from several thousand dollars for restorations to $80,000 or more for full-mouth implant-supported reconstruction. These documented costs form the economic damages component of a claim and are recoverable in litigation. Understanding the cost breakdown helps patients evaluate the potential value of their claim.
How to File a Suboxone Dental Injury Lawsuit
Filing a Suboxone dental injury lawsuit begins with gathering dental and prescription records, consulting a pharmaceutical litigation attorney, and submitting a complaint. Most cases are filed in or transferred to MDL 3092 in the Northern District of Ohio. The process is handled almost entirely by the attorney, with no upfront costs under a contingency fee arrangement.
Suboxone Class Action vs. Individual Claims
Suboxone dental injury litigation is structured as a multidistrict litigation (MDL), not a class action. In an MDL, plaintiffs retain individual claims and individual damages — each client's recovery is based on their specific injuries, not shared with others. Understanding this distinction helps plaintiffs know what to expect from the process.
MAT Patients and Dental Stigma
People in recovery from opioid use disorder who experienced Suboxone-related tooth loss face a unique double stigma: societal bias against addiction, and the unfair association between visible tooth loss and substance use. These psychological and social harms are legally compensable non-economic damages, and addressing them with compassion and dignity is central to how these cases should be litigated.
Suboxone Tooth Decay Lawsuit
Suboxone sublingual film strips — a medication-assisted treatment (MAT) for opioid use disorder — dissolve under the tongue and contain citric acid and other acidic excipients that, with repeated use, erode tooth enamel and cause rapid, severe dental decay. Thousands of patients who faithfully took Suboxone as prescribed to manage opioid dependence later discovered they had lost multiple teeth, required extensive dental reconstruction, or faced thousands of dollars in oral surgery costs — through no fault of their own. Manufacturer Indivior (formerly part of Reckitt Benckiser) knew or should have known about these dental risks for years but failed to include adequate warnings on the product label. The FDA confirmed the danger with a formal safety communication on January 12, 2022, requiring updated product labeling. Patients who suffered dental injuries while using Suboxone sublingual film may have valid product liability claims against Indivior for failure to warn.
View full case overview